EL7.AI
Stocks•8 July 2026•
1 min read

QuidelOrtho Short Interest Rises as Investors Bet Against Recovery

Key Facts

1QuidelOrtho's market cap has dropped by $5B since its 2022 merger, with losses exceeding 40% since February.
2EPS guidance for 2026 was cut twice in three months, with consensus now standing at $1.85 per share.
3The company faces challenges including rising debt, high inventory, weak Chinese sales, and a soft respiratory testing season.

Amid a challenging landscape for medical diagnostics, QuidelOrtho is facing elevated short interest as investors bet against its recovery following persistent earnings uncertainty. The company's market capitalization has eroded by $5 billion since its 2022 merger, with share price losses exceeding 40% since February. This bearish sentiment follows two separate downward revisions to the 2026 EPS guidance within just three months, bringing the consensus down to $1.85 per share.

The company's struggles are compounded by structural hurdles, including rising debt levels, high inventory, and significant sales weakness in the Chinese market. Compared to industry peers, QuidelOrtho has been disproportionately affected by a soft respiratory testing season, which has strained its financial position. Per market data, the lack of a clear strategic mitigation plan from management has further emboldened short sellers who anticipate continued fundamental weakness.

Looking ahead, traders are closely monitoring the upcoming China Services PMI data on July 3, 2026, for clues regarding a potential demand recovery in that key region. Investors should watch for any stabilization in inventory levels as a potential signal for a shift in the current bearish trend.